The gonadotropin-releasing hormone family of neuropeptides in the brain of human, bovine and rat: identification of a third isoform  by Yahalom, Dror et al.
The gonadotropin-releasing hormone family of neuropeptides in the
brain of human, bovine and rat: identi¢cation of a third isoform
Dror Yahaloma;b, Alon Chena, Nurit Ben-Aroyaa, Shai Rahimipoura;b, Ella Kaganovskyc,
Eli Okonc, Mati Fridkinb, Yitzhak Kocha;*
aDepartment of Neurobiology, Weizmann Institute of Science, Rehovot 76100, Israel
bDepartment of Organic Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel
cDepartment of Pathology, Rabin Medical Center, Petah-Tikva 49100, Israel
Received 8 November 1999
Edited by Shmuel Shaltiel
Abstract The mammalian gonadotropin-releasing hormone
(GnRH-I), which regulates reproduction, was the first isoform
of GnRH that was identified in mammals. Recently, we and
others have demonstrated the existence of a second isoform of
GnRH in the brain of mammals. The presence of a third isoform
of GnRH, GnRH-III, in the brain of mammals is reported herein.
GnRH-III, extracted from the brain of bovine and human, was
purified by high performance liquid chromatography, using two
distinct elution programs. In both, GnRH-III was eluted at the
same positions as synthetic salmon GnRH, as demonstrated by
radioimmunoassay. The luteinizing hormone-releasing activity of
purified GnRH-III, using dispersed rat pituitary cells, was found
to be similar to that of synthetic salmon GnRH. The total
amount of GnRH-III, determined by radioimmunoassay, in the
hypothalamus and midbrain of humans and calves is similar to
that of GnRH-I. Immunohistochemical studies demonstrated
GnRH-III-containing neurons in the hypothalamus and midbrain
of human and GnRH-III fibers in the median eminence of rats.
The distribution of GnRH-III in the brain suggests that in
addition to a putative function as a neurohormone at the
hypothalamic^pituitary axis, GnRH-III may have other func-
tions. Our present results suggest that multiple isoforms of
GnRH are present in the brain of mammals, and further studies
are required in order to elucidate their biological functions.
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1. Introduction
The gonadotropin-releasing hormone (GnRH-I, Table 1),
originally isolated from the mammalian hypothalamus, plays
a pivotal role as the physiologic regulator of reproduction
[1,2]. This peptide is synthesized by hypothalamic neurosecre-
tory cells and upon release it reaches the pituitary gland, by
way of a specialized portal system, to induce the synthesis and
secretion of the gonadotropic hormones luteinizing hormone
(LH) and follicle-stimulating hormone. Today, a dozen iso-
forms of GnRH are known in vertebrates, which are con-
served by 50^90% of their sequence as compared to GnRH-
I [3]. In many of the lower vertebrate species, at least two
di¡erent isoforms of GnRH are expressed in the brain [4].
One isoform, [His5,Trp7,Tyr8]GnRH, named GnRH-II (Table
1), originally isolated from chicken brain [5], is expressed in
almost all vertebrate classes. Until recently, only GnRH-I had
been detected in the placental species of mammals [6]. GnRH-
I was suggested to be not only the regulator of the secretion of
the gonadotropic hormones, but also to play a role in a vari-
ety of other functions such as involvement in the regulation of
sexual behavior in rats [7]. Lately, it was reported that a gene
encoding GnRH-II is expressed in the human brain [8]. By
using high performance liquid chromatography (HPLC), im-
munocytochemistry, radioimmunoassay (RIA), and molecular
biology techniques, we have recently demonstrated the pres-
ence of GnRH-II in the brain of mouse, rat and human [9].
The presence of GnRH-II in non-human primates has also
been demonstrated [10].
In several teleost ¢shes, three GnRH isoforms were identi-
¢ed in a single species [11^16]. We have therefore explored the
possibility that multiple GnRH isoforms may be a common
pattern in mammals and have looked for an additional iso-
form of GnRH in the mammalian brain. During our earlier
studies using extracts of human and rat brains [9], we have
observed weak immunoreactivity for GnRH-II in HPLC frac-
tions corresponding to high acetonitrile concentrations that
were used for column wash. Thus, we suspected that a third
GnRH isoform is found in these extracts. This putative iso-
form is very hydrophobic, according to its HPLC elution pro-
¢le, and should cross-react with our GnRH-II antibody.
Based on these indications, we assumed that the immunoreac-
tive peak may correspond to salmon GnRH (sGnRH;
[Trp7,Leu8]GnRH-I, Table 1). sGnRH has a 1.5% cross-reac-
tivity with our GnRH-II antibody (Table 2), and is the most
hydrophobic GnRH isoform known in vertebrates, with the
longest HPLC retention time [17,18]. Our present results in-
deed demonstrate a sGnRH-like peptide in the mammalian
brain.
2. Materials and methods
2.1. Materials
Synthetic GnRH-I, GnRH-II and salmon GnRH were obtained
from Peninsula Laboratories Inc. (San Carlos, CA, USA). Dog¢sh
GnRH (dfGnRH) was synthesized and analyzed in our laboratory,
using previously described procedures [19].
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2.2. Radioiodination and radioimmunoassay
Iodinations of synthetic GnRH-I, GnRH-II or sGnRH were carried
out using the chloramine-T method. Free iodine was removed on a
Sep-Pak C-18 cartridge and the 125I-labeled peptides were separated
from the unlabeled peptides by HPLC. GnRH concentrations in sam-
ples of brain extracts were determined by RIA as previously described
[20].
2.3. Antibodies
The following antisera were used throughout this study: a polyclo-
nal antibody against GnRH-I, prepared and characterized in our lab-
oratory [20]. The speci¢city of this antibody was determined and is
shown in Table 2. A polyclonal antibody against GnRH-II (aCII6)
was kindly provided by Dr. K. Okuzawa (National Research Institute
of Aquaculture, Watarai, Japan), and a polyclonal sGnRH antibody
(sGnRH #2) was kindly donated by Dr. K. Aida (Fish Physiology
Research Group, Department of Aquatic Bioscience, The University
of Tokyo, Japan). The speci¢cities of the two antibodies were previ-
ously de¢ned [14,21,22] and are shown in Table 2. Similar results were
obtained in speci¢city tests conducted in our laboratory, by perform-
ing dose^response studies of the interactions of relevant GnRH iso-
forms with these antibodies.
2.4. Tissue extraction
All animal experiments were carried out in compliance with the
regulations of the Weizmann Institute of Science. Brains from 11-
month-old male calves were obtained at a slaughterhouse and kept
on dry ice for up to 2 h before homogenization. These brains were
processed in two batches, of ¢ve and seven brains per batch. Speci¢c
regions of human brain were received during a routine autopsy at
Rabin Medical Center from a 77-year-old man who died of pyoneph-
rosis and from an 87-year-old man who died of bilateral broncho-
pneumonia. The bodies were kept for 38 h and 21 h, respectively, at
4‡C until autopsy. The brain tissues from both human and cow
were immersed in ice-cold 0.1 N HCl and homogenized by a Te£on-
glass homogenizer. Following centrifugation of each homogenate
(12 000Ug, 30 min at 4‡C), the supernatant was pumped onto Sep-
Pak C-18 cartridges, eluted by methanol and evaporated by nitrogen.
Following the methanol evaporation, all extracts were processed
through reversed phase (RP) HPLC, performed on a Waters system
composed of two Model 510 pumps, Model 680 automated gradient
controller and Model 441 absorbance detector (Waters, Milford, MA,
USA). The HPLC prepacked column which was employed was Li-
chrospher 100 RP-18, 250U4 mm (5 Wm) (Merck, Darmstadt, Ger-
many), and the £ow rate was 1 ml/min. Eluent A, 0.1% tri£uoroacetic
acid (TFA) in water; eluent B, 75% CH3CN in 0.1% TFA. The gra-
dient program consisted of a linear gradient of eluent B 20^30% for
5 min, followed by isocratic elution of 30% eluent B for 30 min,
followed by a linear gradient of eluent B 30^57% in 30 min, and
¢nally column wash using 100% eluent B for 20 min. The fractions
were evaporated to a volume of 0.2 ml and reconstituted with 0.1 M
of phosphate bu¡er (PB, pH 7.4) containing 0.1% of bovine Q-globulin
(Sigma, St. Louis, MO, USA). The HPLC fractions were assayed for
GnRH-I, GnRH-II and sGnRH concentrations by RIA using the
appropriate antisera; three di¡erent aliquots from every fraction
were analyzed in each RIA system. The elution positions of the syn-
thetic peptides were determined by HPLC injection (performed after
all the extracts were eluted) of 100 ng of GnRH-I, GnRH-II, sGnRH
and dog¢sh (df) GnRH, using the same conditions as used for the
extracts. The elution positions were determined using the respective
RIA systems. Between each of the HPLC separations of both extracts
and standards, the column was thoroughly washed, and a blank run
was monitored by RIA to ensure that the column was not contami-
nated. Recovery of peptides in the described extraction process was
estimated by subjecting samples of iodinated GnRH-I, GnRH-II and
sGnRH to identical extraction procedures. The reported amounts of
all peptides were not corrected according to the estimated recovery
(60^70%). Recovery was not improved by using a 80% methanol/20%
0.1 N HCl solution, instead of 0.1 N HCl solution, for tissue extrac-
tion.
2.5. Further puri¢cation
Fractions from HPLC separations of human and cow midbrains
that were found to contain sGnRH-immunoreactive material (see
above) were repuri¢ed in a second HPLC solvent system: eluent A,
0.1% TFA in water; eluent B, 75% isopropanol in 0.1% TFA. The
column which was used was Lichrospher 100 RP-18, 125U4 mm (5
Wm) (Merck, Darmstadt, Germany), and the £ow rate was 0.8 ml/min.
The gradient program consisted of a linear gradient of eluent B 0^20%
for 5 min, followed by a gradient of 20^25% eluent B for 40 min, then
25% eluent B for 5 min, and ¢nally the column was washed using
100% eluent B for 20 min. The fractions collected were evaporated
and subjected to RIA for sGnRH, as detailed above. Synthetic GnRH
markers were also injected in the same system, after all the extracts
were eluted.
2.6. LH release from cultured, dispersed, pituitary cells
Cells from 21-day-old Wistar-derived female rats were dispersed as
previously described [23] and incubated in 96-well plates (50 000 cells/
well) at 37‡C in M-199 medium containing 5% horse serum. After 48 h
the cells were washed with M-199 medium containing 0.1% bovine
serum albumin (BSA) and incubated for 4 h at 37‡C with M-199/0.1%
BSA (0.2 ml) containing the desired concentrations of the various
peptides (three wells/experimental group). The incubation was termi-
nated by removing the medium and diluting it in a ratio of 1:5 with
1% BSA in phosphate-bu¡ered saline (PBS) solution. Three di¡erent
aliquots from each sample were analyzed for LH concentration by
RIA [19], using the kit kindly supplied by the National Institute of
Arthritis, Metabolism and Digestive Diseases (NIAMDD) Rat Pitui-
tary Program. Results are expressed in terms of the RP-3 reference
preparation.
2.7. Immunocytochemical procedures
The localization of GnRH-III in the median eminence, hypothala-
mus and midbrain of rats and humans was carried out by application
of a speci¢c antibody, at a dilution of 1:10 000, to brain slices. This
was followed by a biotinylated secondary antibody and of an avidin^
biotin^horseradish peroxidase complex according to a procedure that
we have previously described [9]. Human brain samples were obtained
during routine autopsies, at Rabin Medical Center, from a 36-week-
old male infant who died of bilateral polycystic kidneys and from an
81-year-old woman who died of pulmonary embolism. The bodies
were kept for 8 h and 13 h, respectively, at 4‡C until autopsy. The
brain samples were ¢xed in 10% neutral bu¡ered formalin, embedded
in para⁄n and sectioned (6 Wm). The processing of the brain of
mature female rats was carried out as described previously [9]. The
sections were incubated for 15 min in 0.3% hydrogen peroxide to
reduce endogenous peroxidase activity, and washed. The sections
were then incubated for 2 h in a blocking medium containing 20%
normal goat serum and 0.5% Triton X-100 to decrease non-speci¢c
staining. The sections were incubated overnight at 4‡C with the anti-
serum (sGnRH#2), rinsed well and incubated for 4 h at room temper-
ature with an avidin^biotin^peroxidase complex followed by nickel-
intensi¢ed diaminobenzidine with hydrogen peroxide as a chromogen,
as described earlier [9]. As controls for the speci¢city of staining we
exposed sections to the antibody that was previously pre-absorbed
with excess sGnRH or that was exposed to a solution from which
the ¢rst antibody was omitted. In these control groups no immuno-
reactive staining was evident.
3. Results
Acid extracts of speci¢c regions of cow and human brain
were eluted through C-18 columns on HPLC, using an elution
program that separates the three peptides of interest : GnRH-
I, GnRH-II and sGnRH (Fig. 1, black arrows). The concen-
trations of these peptides in the eluate of the brain extracts
were determined by RIA using antibodies speci¢c to each
GnRH isoform. Fig. 1 demonstrates that the elution pro¢les
of the immunoreactive neuropeptides that were extracted from
human hypothalamus, midbrain and pituitary stalk were iden-
tical to those of the three synthetic peptides. These results
demonstrate for the ¢rst time the presence of a sGnRH-like
peptide in human brain. The GnRH isoform with the highest
homology to sGnRH among known GnRH isoforms,
dfGnRH (Table 1), cross-reacts with the sGnRH antibody
(Table 2). However, its retention time in the above HPLC
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system is signi¢cantly di¡erent (Fig. 1). The sGnRH immu-
noreactive peak was further puri¢ed using a di¡erent HPLC
system, with an almost isocratic gradient of isopropanol (Fig.
2). Again the extracted sGnRH-immunoreactive material co-
eluted with the synthetic sGnRH in this system, further con-
¢rming the similarity of the extracted material to sGnRH.
The amounts of immunoreactive GnRH-I, GnRH-II and
sGnRH-like peptides found in the various regions of the hu-
man brain (Fig. 1) have to be regarded only qualitatively, as
they represent data that represent only one human brain sam-
ple. We also analyzed by HPLC and RIA an additional hu-
man sample of a combined extract from both hypothalamus
and midbrain. This sample contained 66.1 ng of immunoreac-
tive sGnRH (ir-sGnRH), as compared with a total of 32.2 ng
in the respective regions of the human brain that is presented
in Fig. 1.
In order to obtain qualitative data, we performed an iden-
tical extraction procedure using hypothalami and midbrains
derived from 12 calves, processed in two batches. The hypo-
thalami contained 1.1 ng ir-sGnRH and 8.1 ng ir-GnRH-I per
calf, while the midbrains contained 13.7 ng ir-sGnRH and 0.8
ng ir-GnRH-I per calf. These results demonstrate that in
calves ir-sGnRH is concentrated in the midbrain, while
GnRH-I is more abundant in the hypothalamus.
We tested the LH-releasing activity of the ir-sGnRH using
cultured rat pituitary cells. For this assay, we used GnRH-III
extracted from calf midbrain, which was puri¢ed by the two
HPLC systems that were described above. GnRH-III induced
LH secretion in a dose-dependent manner (Fig. 3) that was
similar in its potency to that of synthetic sGnRH, but much
lower than the activity of GnRH-I. Fractions from a blank
HPLC run, which correspond to the sGnRH-immunoreactive
fractions, were collected as a control for this assay. LH release
in this control group was similar to that of the second control
Table 1
Structure of relevant GnRH isoforms
Underlined residues di¡er from the sequence of GnRH-I.
Table 2
Speci¢city of antisera and RIA systems
Antiserum and titer Percentage cross-reactivity
GnRH-I GnRH-II sGnRH dfGnRH
YK-5 1:120 000 100 6 0.01 6 0.01 ND
aCII6 1:160 000 6 0.01 100 1.46 ND
sGnRH#2 1:240 000 6 0.01 1.58 100 80
The cross-reactivity of GnRH isoforms with antibodies aCII6 and
sGnRH#2 have been reported [14,21,22] and were reevaluated in
our assay systems.
ND, not determined.
Fig. 2. Further puri¢cation of GnRH-III immunoreactive material
from human midbrain by HPLC. An equivalent of 2.5 ng of ir-
sGnRH, obtained as shown in Fig. 1, was eluted from an HPLC
system using a water/isopropanol solvent system with 0.1% TFA.
The isopropanol gradient is indicated by a broken line. Fractions
(0.8 ml) of the eluate were collected, evaporated and reconstituted.
All fractions were assayed for salmon GnRH-immunoreactive mate-
rial, using RIA with speci¢c antibodies for sGnRH. The elution po-
sition of synthetic salmon GnRH is indicated by a black arrow.
GnRH-I and GnRH-II are eluted in this system in fractions 21 and
23, respectively.
Fig. 1. RP-HPLC elution pro¢le of GnRH-I, GnRH-II and GnRH-
III extracted from human midbrain (A), hypothalamus (B), and pi-
tuitary stalk (C), using a water/acetonitrile solvent system with 0.1%
TFA. The acetonitrile gradient is indicated by a broken line. Frac-
tions (1 ml) of the eluate were collected, evaporated and reconsti-
tuted. All fractions were assayed by RIA for GnRH-I, GnRH-II
and sGnRH immunoreactivity, using speci¢c antibodies. The elution
positions of synthetic GnRH-I (I), GnRH-II (II), salmon GnRH (S)
and dog¢sh GnRH (df) are indicated by black arrows.
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group (M-199 containing 0.1% BSA) (2.8 þ 0.7 versus 3.0 þ 0.7
ng/well, respectively).
Immunohistochemical studies (Fig. 4), using the speci¢c
sGnRH antisera, demonstrated sGnRH-immunoreactive neu-
rons in the hypothalamus and midbrain of both human and
rat. As demonstrated in Fig. 4, GnRH-III immunoreactive
granules (black arrows) are seen along nerve ¢bers in the
rat median eminence (A). Immunoreactive GnRH-III neuro-
nal cells (thick bold black arrows) and nerve ¢bers (black
arrows) are found in the human midbrain, ventral to the cer-
ebral aqueduct in the region of the oculomotor nucleus (B), as
well as within the supraoptic area (C) and the preoptic area
(D,E) of the human hypothalamus. Similar results were ob-
tained in the rat hypothalamus and midbrain (data not
shown).
4. Discussion
Using HPLC, RIA and immunocytochemistry, we have
demonstrated the presence of a third GnRH isoform
(GnRH-III) in the brain of cow, rat and human. This isoform
coelutes with synthetic sGnRH in two distinct HPLC systems
(Figs. 1 abd 2) and is recognized by antisera for salmon
GnRH. sGnRH is the most hydrophobic isoform of the
GnRH family and therefore its retention time on HPLC sys-
tems is signi¢cantly higher than that of the other known
GnRH isoforms [17,18]. Thus, our results suggest that
GnRH-III is either sGnRH itself, or a novel isoform that
has identical elution patterns as those of sGnRH. Further-
more, GnRH-III is capable of inducing LH release, from cul-
tured rat pituitary cells, in a dose response pattern that is
similar to that of synthetic sGnRH (Fig. 3).
Salmon GnRH was previously identi¢ed in several ¢sh spe-
cies in combination with GnRH-II, and in some cases also
together with a third GnRH isoform [11^15]. There is also
evidence suggesting the existence of sGnRH, in combination
with GnRH-I, in several amphibian species [24]. Lately, three
GnRH isoforms were detected in a primitive mammal (Hydro-
chaeris hydrochaeris) by a combination of HPLC and RIA
[25]. These isoforms were identi¢ed as GnRH-I, GnRH-II
and sGnRH-like peptides, in agreement with the results pre-
sented herein for higher mammals.
The content of GnRH-III in the brain of humans and of
calves is notable especially in the midbrain, where it is the
dominant form of GnRH, as well as in the hypothalamus,
where a considerable amount of GnRH-III is also found
(Fig. 1). Thus, the total content of GnRH-III in the hypothal-
amus^midbrain unit of calves and humans is similar to that of
GnRH-I. The fact that this isoform was not identi¢ed so far
may be attributed to technical reasons. Being the most hydro-
phobic isoform in the GnRH family of peptides, GnRH-III is
highly adsorbed onto glass or plastic at neutral pH.
Low concentrations of GnRH-III are found in the human
pituitary stalk (Fig. 1C), as compared to the hypothalamus
(Fig. 1B), whereas the total amounts of GnRH-I in the hypo-
thalamus and in the pituitary stalk are similar. As the pitui-
tary stalk is the site of storage of the hypothalamic hypophy-
siotropic neurohormones, these results further suggest that the
anterior pituitary gland is not the main site of GnRH-III
action. However, the demonstration of GnRH-III in neuronal
¢bers of the rat median eminence (Fig. 4A) suggests that
GnRH-III is transported to the pituitary gland by way of
the portal system and may interact with pituitary cells.
We found that the potency of GnRH-III in the induction of
LH secretion from cultured rat pituitary cells is about 2.3% of
that of GnRH-I (Fig. 3). It is therefore unlikely that the main
physiological function of GnRH-III is in the regulation of
gonadotropin secretion, as GnRH-I is known to be. More-
over, the localization of GnRH-III, mainly in the midbrain,
also does not support a central role in the regulation of go-
nadotropin secretion. Thus, the role of GnRH-III in the hy-
pothalamic^pituitary^gonadal axis may be conveyed by mod-
ulation of GnRH-I activity, or by the regulation of GnRH-I
expression or release. In certain ¢shes, sGnRH was reported
to induce release of prolactin [16] or growth hormone [26].
Nevertheless, preliminary results in our laboratory suggest
that GnRH-III, in concentrations which induce LH release
(Fig. 3), does not a¡ect the release of these hormones from
cultured rat pituitary cells. Today, it is evident that each of
almost all neurotransmitters and neuropeptides has more than
one receptor. Therefore, it is hard to conceive that the three
GnRH isoforms that are 70^80% homologous to each other
(Table 1) will share a common, single GnRH receptor. In-
deed, the recent identi¢cation of two GnRH receptors in the
gold¢sh [27] supports the assumption that multiple GnRH
receptors are also present in mammals. The homology in the
structure of the GnRH isoforms, however, may permit some
cross-reactivity of GnRH-III and GnRH-II with the known
mammalian GnRH receptor and thus result in the modulation
of the activity of GnRH-I by these isoforms. Recently, it has
been demonstrated that G protein-coupled receptor heterodi-
merization modulates receptor function. Thus, heterodimeri-
zation of two di¡erent opioid receptors (U and N) resulted in a
new receptor that exhibited ligand binding and functional
Fig. 3. Induction of LH release from dispersed rat pituitary cells by
synthetic GnRH-I and salmon GnRH, as well as by GnRH-III ex-
tracted from calf brain (double-puri¢ed by HPLC). Cells were prein-
cubated for 48 h after dispersion, washed and incubated for 4 h at
37‡C with the examined peptides. Results are the mean þ S.E.M. of
LH concentration (three wells/experimental group). The LH concen-
tration in each well was determined by RIA, using three di¡erent
dilutions of the samples. Two control groups for basal release of
LH were utilized: one contained medium alone and to the other
group, aliquots were added of fractions from a blank HPLC run,
which corresponded to the sGnRH elution pattern. LH release in
these control groups was similar (3.0 þ 0.7 versus 2.8 þ 0.7 ng/well,
respectively). Closed square, basal LH release; open triangles,
GnRH-I; open squares, sGnRH; closed circles, extracted GnRH-
III.
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properties that were distinct from those of either receptor [28].
Similar results were obtained by demonstrating that hetero-
dimerization is required for the formulation of functional
GABAB receptors [29]. Indeed, it has already been demon-
strated that dimerization of the GnRH receptor is essential
for the induction of LH secretion [30,31]. The existence of
several isoforms of GnRH that are capable of interaction
with the known GnRH receptor, and the possible prevalence
of additional, putative GnRH receptor(s) present multiple
possibilities for the regulation of GnRH activity by hetero-
dimerization.
GnRH-I was previously suggested to be involved in the
induction of sexual behavior, since the administration of
this peptide into the midbrain central gray of rats has been
demonstrated to facilitate sexual behavior [7]. However, high
doses of GnRH-I (WM range) were needed to elicit this e¡ect.
Also, discrepancies are evident between the reported biolog-
ical potency of various GnRH-I analogs in the pituitary gland
as compared to their potency in the brain. Therefore, the
discovery of both GnRH-II and GnRH-III in the midbrain
raises the possibility that either of these may serve as the
physiological regulator of reproductive behavior.
The observation that three isoforms of GnRH are localized
in identical brain regions of the mammalian brain (i.e. hypo-
thalamus, midbrain, pituitary stalk) may suggest that these
isoforms evolved from a common ancestor, by gene duplica-
tions and mutations. Later, these isoforms assumed distinct
biological activities, although they may share some activities
due to their structural similarities. The physiological signi¢-
cance of the existence of multiple isoforms of GnRH in the
brain is not clear as yet, and unveiling their physiological
functions is a challenge for future research. Nevertheless,
our current conceptions on the neuroendocrine control of
reproduction, as well as on the physiological functions of
the di¡erent members of the GnRH family, have to be reeval-
uated.
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Fig. 4. Immunoreactive GnRH-III neuronal cells and ¢bers in coronal sections through the median eminence of a mature female rat (A), of
the midbrain area from a 36-week-old infant (B), and of the hypothalamus from an 81-year-old women (C^E). In the rat median eminence,
GnRH-III immunoreactive material (black arrows) is packed as dark granules lined along the neuronal ¢bers. In the human midbrain (B),
GnRH-III immunoreactive neurons (thick bold arrows), and their processes (black arrows) are in the area of the oculomotor nucleus. Clusters
of immunoreactive neurons are also found within the area of the supraoptic nucleus (C) and the preoptic area (D,E) of the human hypothala-
mus. Figures B^E were also stained by hematoxylin to demonstrate nuclei of cells (white arrows). 3V, third ventricle. A, U240; B,C, U64; D,
U32; E, U160.
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